<DOC>
	<DOC>NCT02480166</DOC>
	<brief_summary>The primary objectives of this study are to describe the efficacy of: 1. 8-week treatment of SOF/LED for treatment-naïve, non-cirrhotic, HCV genotype 6 2. 12-week treatment of SOF/LED for all other HCV-6 populations</brief_summary>
	<brief_title>Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6</brief_title>
	<detailed_description>The secondary objective of this study is to describe safety, persistency, and tolerability of SOF/LED in patients with HCV-6.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>1. Male or female, age ≥18 years 2. HCV genotype 6 or indeterminate and later assessed at Screening and confirmed as genotype 6 3. Selected to start on treatment by their treating providers 4. Willing and able to provide informed consent 5. Able to comply with dosing instructions for study drug administration and able to complete the study schedule of assessments 6. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative pregnancy test on Baseline 7. Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception 8. Lactating females must agree to discontinue nursing before the study drug is administered 1. Previous recipient of a liver transplant 2. Coinfection with human immunodeficiency virus (HIV) or hepatitis B (HBV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hepatitis C, genotype 6</keyword>
</DOC>